AzTrials
AzTrials

Ventricular FibrillationEuroEcoNCT00776087

European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)

A study testing Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring in people with Ventricular Fibrillation and Tachycardia, Ventricular, run by Biotronik SE & Co. KG at 17 sites in 6 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer. The EuroEco study: 1. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
409 participants
Where
17 sitesin 6 countries
Study dates
17 Oct 2008to 27 Oct 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

ICD Patient Population - Inclusion Criteria

  • Indication for 1-/2- chamber ICD implantation, including replacement indication
  • Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent

ICD Patient Population - Exclusion Criteria

  • Patients with contraindication to ICD implantation
  • Patients with indication for cardiac resynchronization (CRT)
  • Minors and pregnant women
  • Patients participating in another study

CRT-D Patient Population - Inclusion Criteria

  • Patients with indication for de novo CRT-D implantation according to current guidelines
  • Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent

CRT-D Patient Population - Exclusion Criteria

  • Patients who had a cardiac device implanted before (upgrade, device replacement)
  • Life expectancy less than 12 months
  • Planned heart transplantation
  • NYHA IV
  • Minors < 18 years
  • Pregnant and breast-feeding women
  • Participation in another clinical study

Trial locations and contacts

17 sites in 6 countries.

17 sites in 6 countries

Belgium4 sites
  • Heart Rhythm Management Institute, Free University of Brussels

    Brussels

  • Ziekenhuis Oost Limburg, Campus St. Jan

    Genk

  • Jessa Ziekenhuis (Campus Virga Jesse)

    Hasselt

  • ZU Gasthuisberg

    Leuven

Other trials in Belgium

Germany4 sites
  • Helios Klinikum Aue

    Aue, 08280

  • Charité Berlin Campus Mitte

    Berlin, 10117

  • Städt. Klinikum St. Georg gGmbH

    Leipzig, 04129

  • Herzzentrum Leipzig, Abteilung Rhythmologie

    Leipzig

Other trials in Germany

Spain4 sites
  • Hospital Universitario La Paz

    La Paz

  • Hospital Universitario Puerta de Hierro Majadahonda

    Madrid

  • Hospital Ntra.Sra.de la Candelaria

    Santa Cruz de Tenerife

  • Arrythmia Unit, Complejo Hospitalario de Vigo (Hospital Xeral)

    Vigo

Other trials in Spain

United Kingdom3 sites
  • Cardiology, Aberdeen Royal Infirmary

    Aberdeen

  • Cardiology, St. Peters Hospital/St. George's

    Chertsey

  • Cardiology; Raigmore Hospital

    Inverness

Other trials in United Kingdom

Finland1 site
  • University of Oulu

    Oulu, 90014

Other trials in Finland

Netherlands1 site
  • Leiden Universitair Medisch Centrum

    Leiden, 2333

Other trials in Netherlands

About this study

BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer.

The EuroEco study:

  1. Outlines a new HM-based FU model for the ICD and CRT-D patients that combines in-clinic consultations and regular check ups of the patient/ICD/CRT-D data received through the HM service.
  2. Compares the direct costs for physicians and clinics for the HM-based FU of ICD and CRT-D patients versus the traditional FU.
  3. Compares the indicators of patients' safety between the two FU models.
Read the detailed description

The EuroEco is a prospective, international, randomized study aimed at assessing the economic effects of BIOTRONIK Home Monitoring (HM) technology as compared with traditional follow up (FU) of ICD and CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on the physician, hospital and patient. The study outlines a new model for the FU of ICD-and CRT-D patients based on a combination of in-clinic consultations and regular check ups of the patient data received through the HM service.

About 312 patients with an indication for ICD therapy and 104 patients with an indication for de novo CRT-D implantation should be enrolled. All patients will be implanted with BIOTRONIK ICD or CRT-D devices from the Lumax families and randomized (1:1) to the traditional, or to HM-based FU model. Traditional FU will be performed according to the local clinical practice. Patients in the HM study arm will first undergo local clinical FU routine until the first in-clinic visit after patient discharge. Thereafter routine in-clinic FUs are scheduled at 12 and 24 months. Three HM data checks should be carried out during each 12-month interval, to assess the patient/ICD/CRT-D status remotely.

In both (HM and no HM) groups, additional in-hospital FU may be scheduled any time the patients reports symptoms which are presumed to be cardiovascular symptoms. In the HM group, additional in-clinic FU may also be scheduled as a result of specific HM findings.

The following FU-related activities were accounted for: in-clinic consultations, patients contact, discussion with colleague physician, nurse or technician and arranging in clinic consultation. In HM patients, two additional HM-related FU activities were taken into account: 1) checking the website of BIOTRONIK HM Service Center, and 2) checking HM-related emails and faxes (provided by BIOTRONIK HM Service Center)..

Several tools were made available to document the time that physicians, nurses and technicians spend with these FU activities without disrupting their clinical routine much:

  • designated case report forms
  • a web-based time measurements software.

A user manual for time measurements was handed out to physicians, nurses and technicians to recommend which tool should be used in which clinical situation. The average time per patient followed according to the traditional FU model and the average time per patient followed by the HM-based FU model will be calculated for each of the three health care professionals considered (physicians, nurses and technicians). The difference in costs between the traditional and the HM-based FU will be assessed for statistical significance.

This trial may provide data warranting a change in the guidelines for the use of ICD and CRT-D devices featuring HM function, in that HM may justify a prolongation of the time interval between statutory routine in-clinic FU visits. Coupled with the fact that the information provided by HM helps physicians to recognize some otherwise unsuspected needs for additional FU visits, this may ultimately result in better and more cost-effective health care for all parts involved (patients, providers and payers).

Being tested
Home Monitoring provided by Biotronik ICD and CRT-D devices, No Home Monitoring
Keywords
Medical costs, Telemonitoring, Implantable cardioverter-defibrillator
Medical subject headings
Ventricular Fibrillation, Tachycardia, Ventricular, Ventricular Flutter

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Home Monitoring provided by Biotronik ICD and CRT-D devicesDevice

    Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety

  • No Home MonitoringDevice

    Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).

Study groups in NCT00776087
Study groupRoleWhat they receive
1 = Home MonitoringExperimentalRemote monitoring of ICD and CRT-D function and patient status
Receives: Device: Home Monitoring provided by Biotronik ICD and CRT-D devices
2 = No Home MonitoringActive comparatorHome Monitoring option is switched off
Receives: Device: No Home Monitoring

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Euro spent to follow up ICD and CRT-D patients

    Measured: 26 months

Secondary outcomes (7)
  1. Average number of in-hospital follow-up visits per patient

    Measured: 26 months

  2. Time to first in-hospital follow-up visit beyond the first post-implantation visit

    Measured: 12 months

  3. Effective financial impact on hospitals / physicians

    Measured: 26 months

  4. Proportion of in-hospital consultations with relevant findings (i.e. necessitating changes in medical therapy, device programming or re-hospitalisations/ interventions)

    Measured: 26 months

  5. Proportion of patients with HM-triggered interventions that, without remote monitoring, would have first been discovered at a subsequent scheduled follow-up

    Measured: 26 months

  6. Incidence of inappropriate ICD shocks

    Measured: 26 months

  7. Changes in quality-of-life (SF-36) from baseline to the 12- and to 24-month follow-up visits

    Measured: 26 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2008 (estimated)
  2. Study start17 Oct 2008
  3. Primary completion21 Jul 2016
  4. Study completion27 Oct 2016

Why it stopped: it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized prospective multicenter international clinical trial
Masking
None (open label)
Enrolment
409 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00776087
Sponsor's protocol ID
HS043
Acronym
EuroEco
Status last verified
Jun 2017
First submitted
17 Oct 2008
Last updated
2 Jul 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring in people with Ventricular Fibrillation and Tachycardia, Ventricular, run by Biotronik SE & Co. KG at 17 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 2 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in Belgium, Germany, Spain, United Kingdom, Finland and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Euro spent to follow up ICD and CRT-D patients (time frame: 26 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2017; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in